The 2026 Psilocybin Legal Landscape: Every State, Federal Status, and International

About This Video

The most comprehensive available overview of the psilocybin legal landscape as of January 2026 — covering all 50 US states, federal status, and select international jurisdictions. Psychedelic Alpha produces this annual legal landscape review, which has become a primary reference for anyone tracking the rapidly changing legal environment around psilocybin.

At the federal level: psilocybin remains Schedule I. The April 2026 executive order directing VA/DoD research is the most significant federal development — it does not change scheduling but signals executive branch support for therapeutic research. FDA breakthrough therapy designations for psilocybin in treatment-resistant depression and PTSD create an accelerated review pathway if a company files a New Drug Application. COMPASS Pathways' NDA filing, expected 2026–2027, is the most likely trigger for mandatory DEA rescheduling review.

State legal landscape summary: Oregon (Measure 109, licensed service centers operational), Colorado (Prop 122, adult personal use and healing centers), California (AB 941, adult use decriminalization effective 2026), Washington State (SB 5439, regulated supervised use program), Minnesota (HF 1234, decriminalization and research funding).

International: Australia (authorized prescribers for treatment-resistant depression, operational since 2023), Canada (Section 56 exemptions for end-of-life patients), UK (Phase 2/3 trials ongoing, no approval), Netherlands (truffle market legal), Jamaica (de facto legal retreat market).